MMMargaret M. Madeleine

Margaret M. Madeleine

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Margaret M. Madeleine has a total of 56 co-authors. Here are the top co-authors by number of shared publications:

  • Denise A. Galloway

    Public Health Science, Fred Hutchinson Cancer Research Center, Seattle, WA; 2Department of Epidemiology, University of Washington, Seattle, WA; 3Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA; and 4Department of Microbiology, University of Washington, Seattle, WA

    5 shared publications
  • Lisa G. Johnson

    Public Health Science, Fred Hutchinson Cancer Research Center, Seattle, WA; 2Department of Epidemiology, University of Washington, Seattle, WA; 3Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA; and 4Department of Microbiology, University of Washington, Seattle, WA

    5 shared publications
  • Janet R. Daling

    Program in Epidemiology Fred Hutchinson Cancer Research Center Seattle Washington

    4 shared publications
  • Joseph J. Carter

    Public Health Science, Fred Hutchinson Cancer Research Center, Seattle, WA; 2Department of Epidemiology, University of Washington, Seattle, WA; 3Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA; and 4Department of Microbiology, University of Washington, Seattle, WA

    3 shared publications
  • Stephen M. Schwartz

    Program in Epidemiology Fred Hutchinson Cancer Research Center Seattle Washington

    3 shared publications
  • Anajane G. Smith

    Human Immunogenetics Program, Fred Hutchinson Cancer Research Center, Seattle

    2 shared publications

Latest Publications

  • Open Access

    Natural Antibodies to Human Papillomavirus 16 and Recurrence of Vulvar High-Grade Intraepithelial Neoplasia (VIN3)

    by Margaret M. Madeleine, Lisa G. Johnson, David R. Doody, Elaine R. Tipton, Joseph J. Carter, Denise A. Galloway

    Objectives Approximately 30% of women treated for squamous high-grade intraepithelial neoplasia (VIN3), often associated with human papillomavirus (HPV), have recurrent disease. In this study, we assess predictors of recurrence that may provide targets for early prevention or treatment. Materials and Methods Women with VIN3 who participated in a previous population-based case-control study with blood and tumor samples completed a follow-up telephone interview an average of 5 years after initial diagnosis. The risk of recurrence was determined by proportional hazards modeling. Results Women with VIN3 in the follow-up study (n = 65) were similar to women with VIN3 in the parent study (n = 215) with regard to age at primary diagnosis, level of current cigarette smoking (>60%), and lifetime number of partners. We found that 22 (33.8%) of 65 participants had a vulvar recurrence and that 73.4% recurred within 3 years of treatment. Recurrences occurred more often among women with common warts in the decade before diagnosis (hazard ratio [HR] = 2.5, 95% CI = 1.1–5.8) and among those with a previous anogenital cancer (HR = 2.7, 95% CI = 1.2–6.3). Interestingly, recurrence was less frequent among women who mounted a natural antibody response to HPV16 (HR = 0.4, 95% CI = 0.2–0.9). Conclusions These data provide strong preliminary evidence that VIN3 recurrence was less frequent among those with HPV16 antibodies. Vaccination with the currently licensed HPV vaccine as part of adjunctive therapy for VIN3 would increase antibody response and may decrease risk of recurrence. Randomized controlled trials are needed to determine whether HPV vaccination is effective against VIN3 recurrence.


  • Open Access

    Risk of squamous cell skin cancer after organ transplant associated with antibodies to cutaneous papillomaviruses, polyomaviruses, and TMC6/8 (EVER1/2) variants

    by Margaret M. Madeleine, Joseph J. Carter, Lisa G. Johnson, Gregory C. Wipf, Connie Davis, Daniel Berg, Karen Nelson, Janet R. Daling, Stephen M. Schwartz, Denise A. Galloway

    Squamous cell skin cancer (SCSC) disproportionately affects organ transplant recipients, and may be related to increased viral replication in the setting of immune suppression. We conducted a nested case–control study among transplant recipients to determine whether SCSC is associated with antibodies to cutaneous human papillomaviruses (HPV), to genes associated with a rare genetic susceptibility to HPV (TMC6/TMC8), or to human polyomaviruses (HPyV). Cases (n = 149) had histologically confirmed SCSC, and controls (n = 290) were individually matched to cases on time since transplant, type of transplant, gender, and race. All subjects had serum drawn immediately prior to transplant surgery. Antibodies to 25 cutaneous HPVs and six HPyVs were assayed by detection of binding to virus‐like particles, and 11 TMC6/8 variants were genotyped. After correction for multiple comparisons, only antibodies to HPV37 were associated with SCSC (OR 2.0, 95% CI 1.2–3.4). Common genetic variants of TMC6/8 were not associated with SCSC, but three variants in TMC8 (rs12452890, rs412611, and rs7208422) were associated with greater seropositivity for species 2 betapapillomaviruses among controls. This study suggests that some betaHPVs, but not polyomaviruses, may play a role in the excess risk of SCSC among transplant recipients.


  • Open Access

    HPV-Related Cancers After Solid Organ Transplantation in the United States

    by M. M. Madeleine, J. L. Finch, C. F. Lynch, M. T. Goodman, E. A. Engels


  • Open Access

    Genetic variation in TLR or NFkappaB pathways and the risk of breast cancer: a case-control study

    by Alexa J Resler, Kathleen E Malone, Lisa G Johnson, Mari Malkki, Effie W Petersdorf, Barbara McKnight, Margaret M Madeleine

    Toll-like receptors (TLRs) and the transcription factor nuclear factor-κB (NFκB) are important in inflammation and cancer.


  • Open Access

    Cohort Profile: The Skin Cancer After Organ Transplant Study

    by Margaret M Madeleine, Lisa G Johnson, Janet R Daling, Stephen M Schwartz, Joseph J Carter, Daniel Berg, Karen Nelson, Connie L Davis, D. A. Galloway

    The Skin Cancer after Organ Transplant (SCOT) study was designed to investigate the link between genus beta human papillomavirus (HPV) and squamous cell skin cancer (SCSC). We focused on a population receiving immunosuppressive therapy for extended periods, transplant patients, as they are at extremely high risk for developing SCSC. Two complementary projects were conducted in the Seattle area: (i) a retrospective cohort with interview data from 2004 recipients of renal or cardiac transplants between 1995 and 2010 and (ii) a prospective cohort with interview data from 328 people on the transplant waiting lists between 2009 and 2011. Within the retrospective cohort, we developed a nested case–control study (172 cases and 337 control subjects) to assess risk of SCSC associated with markers of HPV in SCSC tumour tissue and eyebrow hair bulb DNA (HPV genotypes) and blood (HPV antibodies). In the prospective cohort, 135 participants had a 1-year post-transplant visit and 71 completed a 2-year post-transplant visit. In both arms of the cohort, we collected samples to assess markers of HPV infection such as acquisition of new types, proportion positive for each type, persistence of types at consecutive visits and number of HPV types detected. In the prospective cohort, we will also examine these HPV markers in relation to levels of cell-mediated immunity. The goal of the SCOT study is to use the data we collected to gain a more complete understanding of the role of immune suppression in HPV kinetics and of genus beta HPV types in SCSC. For more information, please contact the principal investigator through the study website: http://www.fhcrc.org/science/phs/cerc/The_SCOT_Study.html.


  • Genetic variation in proinflammatory cytokines IL6, IL6R, TNF-region, and TNFRSF1A and risk of breast cancer

    by Margaret M. Madeleine, Lisa G. Johnson, Mari Malkki, Alexa J. Resler, Effie W. Petersdorf, Barbara McKnight, Kathleen E. Malone

    Proinflammatory cytokines are associated with age-related diseases including arthritis and heart disease. IL6 and TNF also play key roles in estrogen modulation in older women. We explored whether variation in IL6 and TNF genes influenced the risk of breast cancer in samples that differed by age group: T alleles at IL6 rs2069861 among subjects in the oldest age group (OR 1.8, 95% CI 1.1–2.9), but no overall increased risk of breast cancer associated with any IL6 or IL6R variants in the combined data. There were significantly elevated risks of breast cancer among women 45–64 years old associated with a UTR 5′ flanking SNP LTA rs2009658 C>G allele (OR 1.5, 95% CI 1.1–1.9) and a nonsynonomous coding SNP TNFRSF1A rs767455 T>C allele (OR 1.3, 95% CI 1.1–1.6); these two variants were also elevated in the combined data (OR 1.3, 95% CI 1.1–1.5 and OR 1.2, 95% CI 1.1–1.4, respectively). This study supports a modest association between a variant in IL6 and breast cancer among older women and TNF-related variants and breast cancer among middle-aged women. Further evaluation of these genes in other studies is warranted.


  • Genetic variation in CXCL12 and risk of cervical carcinoma: a population-based case–control study

    by S. N. Maley, S. M. Schwartz, L. G. Johnson, M. Malkki, Q. Du, J. R. Daling, S. S. Li, L. P. Zhao, E. W. Petersdorf, M. M. Madeleine

    CXCL12 provides a chemotactic signal‐directing leucocyte migration and regulates metastatic behaviour of tumour cells. We conducted a population‐based case–control study to test the hypothesis that common genetic variation in CXCL12 individual single nucleotide polymorphism (SNP) alleles and haplotypes] is associated with the risk of cervical carcinoma. Cases (n = 917) were residents of western Washington State diagnosed with invasive squamous cell cervical carcinoma (SCC), invasive adenocarcinoma or adenosquamous carcinoma, or adenocarcinoma in situ of the cervix. Control participants (n = 849) were identified from the source population by random digit telephone dialling and frequency matched to cases on county and age. Nine CXCL12 tagSNPs chosen from the SeattleSNPs database were genotyped. The minor allele of intronic SNP rs266085 was inversely associated with cervical cancer under a recessive genetic effects model (OR = 0.74, 95% CI: 0.56–0.98). Among the ten common haplotypes inferred from the nine tagSNPs, one haplotype defined by minor alleles at 5′‐flanking SNP rs17885289 and rs266085, and common alleles at the other seven SNPs occurred among 7.8% of cases and 10.6% of controls (dominant model OR = 0.72, 95% CI: 0.56–0.93; recessive model OR = 0.35, 95% CI: 0.12–0.97; and log‐additive model OR = 0.72, 95% CI: 0.57–0.90). A stepwise procedure identified rs17885289, rs266085 and 3′‐untranslated region (UTR) SNP rs266093 as the most parsimonious subset of SNPs necessary to define the haplotype inversely associated with cervical cancer risk in our study. A 3′‐UTR SNP, rs1801157, previously found to be related to HIV pathogenesis, was not associated with cervical cancer risk. Further population‐based studies are warranted to confirm these associations between genetic variation in CXCL12 and cervical cancer risk.


  • Open Access

    Comprehensive Analysis of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 Loci and Squamous Cell Cervical Cancer Risk

    by Margaret M. Madeleine, Lisa G. Johnson, Anajane G. Smith, John A. Hansen, Brenda B. Nisperos, Sue Li, Lue-Ping Zhao, Janet R. Daling, Stephen M. Schwartz, Denise A. Galloway

    Variation in human major histocompatibility genes may influence the risk of squamous cell cervical cancer (SCC) by altering the efficiency of the T-cell–mediated immune response to human papillomavirus (HPV) antigens. We used high-resolution methods to genotype human leukocyte antigen (HLA) class I (A, B, and Cw) and class II (DRB1 and DQB1) loci in 544 women with SCC and 542 controls. Recognizing that HLA molecules are codominantly expressed, we focused on co-occurring alleles. Among 137 allele combinations present at >5% in the case or control groups, 36 were significantly associated with SCC risk. All but one of the 30 combinations that increased risk included DQB1*0301, and 23 included subsets of A*0201-B*4402-Cw*0501-DRB1*0401-DQB1*0301. Another combination, B*4402-DRB1*1101-DQB1*0301, conferred a strong risk of SCC (odds ratio, 10.0; 95% confidence interval, 3.0–33.3). Among the six combinations that conferred a decreased risk of SCC, four included Cw*0701 or DQB1*02. Most multilocus results were similar for SCC that contained HPV16; a notable exception was A*0101-B*0801-Cw*0701-DRB1*0301-DQB1*0201 and its subsets, which were associated with HPV16-positive SCC (odds ratio, 0.5; 95% confidence interval, 0.3–0.9). The main multilocus associations were replicated in studies of cervical adenocarcinoma and vulvar cancer. These data confirm that T helper and cytotoxic T-cell responses are both important cofactors with HPV in cervical cancer etiology and indicate that co-occurring HLA alleles across loci seem to be more important than individual alleles. Thus, certain co-occurring alleles may be markers of disease risk that have clinical value as biomarkers for targeted screening or development of new therapies. [Cancer Res 2008;68(9):3532–9]


  • Open Access

    Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors

    by Margaret M. Madeleine, Tarja Anttila, Stephen M. Schwartz, Pekka Saikku, Maija Leinonen, Joseph J. Carter, Michelle Wurscher, Lisa G. Johnson, Denise A. Galloway, Janet R. Daling

    Human papillomavirus (HPV) is the central etiologic factor for cervical cancer, and prior studies suggested C. trachomatis may act as an HPV cofactor. We examined the C. trachomatis ‐cervical cancer association by serotype, histology, HPV type in the tumor, and other HPV cofactors. We conducted a population‐based study in the Seattle‐Puget Sound area of 302 women with invasive squamous cell carcinomas (SCC), 185 women with adenocarcinomas of the cervix (AC), and 318 HPV seropositive control women. The risk of SCC associated with antibodies to C. trachomatis was increased (OR 1.6, 95% CI 1.1–2.2) but not for AC (OR 1.0, 95% CI 0.6–1.5). This association was independent of HPV type in the SCC tumor tissue. There was an association between specific serotypes of C. trachomatis and SCC for 6 of the 10 serotypes: B (OR 3.6, 95% CI 1.5–8.4), D (OR 2.1, 95% CI, 1.2–3.5), E (OR 2.4, 95% CI, 1.4–3.9), G (OR 3.0, 95% CI, 1.1–7.9), I (OR 4.2, 95% CI, 1.5–11.7), and J (OR 2.3, 95% CI, 1.0–5.1), but not for the 4 types (C, F, H, and K) that were present at very low prevalence in this population. There was an increased risk of SCC, but not AC, associated with antibodies to C. trachomatis that was not serotype specific.


  • Open Access

    Human Leukocyte Antigen Class II and Cervical Cancer Risk: A Population‐Based Study

    by Margaret M. Madeleine, Babette Brumback, Kara L. Cushing‐Haugen, Stephen M. Schwartz, Janet R. Daling, Anajane G. Smith, J. Lee Nelson, Peggy Porter, Katherine A. Shera, James K. McDougall, et al.

    The critical role of the human leukocyte antigen (HLA) system in presenting peptides to antigen-specific T cell receptors may explain why only some h